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ABSTRACT
Low muscle mass (LMM) and low muscle density (LMD) are increasingly recognized as prognos-
tic factors for survival in different malignancies. This study determined the association of LMM
and LMD with survival in DLBCL (diffuse large B-cell lymphoma) patients. CT-based measure-
ment of muscle was performed in 164 DLBCL patients prior to chemo-immunotherapy. Z-scores
adjusted for gender, age, and body mass index were derived from a healthy reference popula-
tion. LMM or LMD were defined as a Z-score below 1 and were related to OS and PFS. The
co-existence of both LMM and LMD was observed in 13% of the DLBCL patients and was signifi-
cantly associated with shorter OS and PFS. Also, these patients more often did not complete the
planned treatment. The combination of LMM and LMD is an independent prognostic factor for
survival in DLBCL patients. This may guide clinical decision-making in patients with suspected
insufficient performance to benefit from chemo-immunotherapy in standard doses.
KEY POINTS
 Patients with DLBCL have low muscle mass (LMM) and low muscle density (LMD) compared
to healthy counterparts.
 The combination of LMM and LMD is a negative prognostic factor for survival, independent
of comorbidities and unfavorable lymphoma characteristics.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon type of non-Hodgkin lymphoma (NHL), account-
ing for approximately 30% of all NHL cases [1].
Treatment usually consists of chemotherapy combined
with monoclonal antibody rituximab (R-CHOP), result-
ing in a complete remission (CR) rate in 65–70% and a
5-year overall survival (OS) of 40–65% [2]. Clinical out-
comes might be compromised by the fact that some
patients are unable to complete the entire chemothera-
peutic treatment due to toxicity or comorbidity or they
are unable to receive the first choice treatment (R-
CHOP) at all [3]. The determination of factors contribu-
ting to physical reserve or the occurrence of treatment
toxicity is clinically relevant to optimize the administra-
tion of systemic treatment to patients with DLBCL.
In recent years, the impact of body composition
parameters on prognosis and treatment tolerability
has been extensively studied in the oncological field.
Body composition analyses consist of the measure-
ment of different body compartments, which is fat-
free mass (FFM) and fat mass (FM), where muscle
mass is part of the FFM. Low muscle mass (LMM) has
been related to impaired OS in multiple tumor types
[4–6], including DLBCL [7–11]. More recently, it has
been demonstrated that the quality of the muscle
fibers is even more important than the amount of
muscle mass itself. More microscopic fatty infiltration
of muscle (resulting in lower muscle density) showed
a larger association with survival than LMM in breast
cancer, renal cell carcinoma, and gastric cancer
[11–14]. One study in patients with DLBCL indeed
showed that low muscle density (LMD) resulted in a
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shorter median OS (HR: 2.52, 95% CI: 1.40–4.54,
p¼ 0.002) after adjustment for gender and R-IPI score
[11]. However, a high R-IPI score remained the most
important prognostic factor for outcome in this study
and a majority of the patients with a high R-IPI had
LMD. Therefore, it is unclear whether the prognostic
impact is partly due to old age or unfavorable charac-
teristics of DLBCL in these patients. A problem with
studies reporting LMM and LMD is that different defi-
nitions of LMM and LMD are used, making it hard to
generalize the results.
Therefore, we performed a study to investigate the
association of LMD, LMM and the combination of both
with survival in patients with DLBCL with special
emphasis on investigating differences in comorbidity
and received treatment between these patient groups.
Secondly, we determined the prevalence of LMM and
LMD in patients with DLBCL compared to a recently
published reference population of healthy kidney
donors. We applied a reproducible formula for LMM
and LMD based on the healthy reference population,
as a first step in the standardization of muscle
measurement.
Methods
Study design
This single-center retrospective study was performed at
a large regional hospital in the Netherlands. Patients
diagnosed with DLBCL between January 2006 and
December 2015 were identified using the Netherlands
Cancer Registry (NCR). The date of the last known vital
status (i.e. alive, dead, or emigration) was retrieved by
linking the NCR to the Nationwide Population Registries
Network that holds vital statistics of all residents in the
Netherlands. Patients with abdominal CT scans within 3
months before the start of treatment were included.
Inclusion criteria were: A histological diagnosis of DLBCL,
18 years of age and treatment with R-CHOP chemo-
immunotherapy. Exclusion criteria were: a second active
malignancy or a history of malignant lymphoma in the
past. Medical records were searched for patient charac-
teristics, length, weight, chemotherapeutic dosage, and
tumor response.
The primary endpoint was OS. Secondary endpoints
were progression-free survival (PFS), the CR-rate and the
completion of the planned treatment. OS was defined as
the date of the pathological diagnosis to the date of
death or end of follow-up (1 July 2017). PFS was defined
as the date of the pathological diagnosis until the date
of radiological disease progression. Alive patients and
patients without disease progression were censored on
1 July 2017. Response to treatment was defined accord-
ing to the revised response criteria for malignant lymph-
oma [15]. The study was approved by the Ethics
Committee of the Albert Schweitzer hospital and the
Internal Review Board of the NCR.
Muscle measurements
Muscle mass was measured by CT-imaging (slice thick-
ness 3mm, Brilliance 64 CT or Brilliance 40 CT, Philips,
Best, the Netherlands), acquired during routine patient
care. All measurements were performed using a single
transversal CT-image at the L3 level using validated seg-
mentation software (sliceOmatic, TomoVision, Montreal,
Canada) (tomovision.com/products/sliceomatic.html).
Skeletal muscle at this level is representative of the
whole body [16]. Total abdominal muscle cross-sectional
area was measured in cm2 and corrected for height,
resulting in a lumbar skeletal muscle index in cm2/m2,
which is used as marker of muscle mass. Mean muscle
density of all abdominal muscles at L3 was measured in
Hounsfield units (HU). The HU-threshold for muscle tis-
sue varied from 29 to þ150 HU [17]. Recently, sex-spe-
cific percentiles for muscle mass and muscle density
were determined in more than one thousand healthy
individuals of a predominantly Caucasian population
[18]. Z-scores for muscle mass and muscle density were
used from this population, with Z-scores of 0 indicating
the mean muscle mass and muscle density in the
healthy population. These Z-scores were adjusted for
gender, age, and body mass index (BMI). LMM and LMD
were defined as a Z-score equal to or below 1, which
corresponds with one standard deviation below the
mean of the healthy population. Both populations
(DLBCL and healthy) were from the Netherlands and
mainly Caucasian.
All muscle measurements were performed by one
trained investigator (HK). The inter-observer reliability
with two other trained investigators (HR, MK) was
high, as assessed with an intraclass correlation coeffi-
cient using a two-way random effects model and an
absolute agreement definition of 0.993.
Statistical analyses
Continuous variables were described as mean and
standard deviation or as median and interquartile
range (IQR). Categorical variables were described using
percentages. Comparisons between patients with and
without LMM or LMD were performed using
Mann–Whitney tests for continuous variables, Fisher’s
exact tests for dichotomous variables and chi-square
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tests for categorical variables with more than two cat-
egories. Mean muscle mass and mean muscle density
between the patients with DLBCL and healthy individ-
uals were compared using t-tests. Z-scores for muscle
mass were derived from the healthy population [18]
according to the following formulas using the inter-
cept regression coefficients:
Muscle mass in males
¼ ðmuscle skeletal index in cm2=m2  32:32þ 0:14
 age 1:13 BMIÞ=7:02
Muscle mass in females
¼ ðmuscle skeletal index in cm2=m2  19:89 0:19
 age 1:07 BMIþ 0:01 age BMIÞ=5:16
Muscle density in males
¼ ðmuscle density in HU 77:33þ 0:29 age
þ 0:69 BMIÞ=7:12
Muscle density in females
¼ ðmuscle density in HU 83:63þ 0:38 age
þ 0:83 BMIÞ=8:36
The relation between muscle parameters and
comorbidity and premature termination of R-CHOP
treatment was determined using multivariable logistic
regression models. In separate models, premature ter-
mination of R-CHOP and the presence of LMM or LMD
were used as dependent variables. Age, BMI, IPI score,
gender, and comorbidity were the independent varia-
bles. The association of LMM, LMD with OS and PFS
were determined using Kaplan–Meier curves and Cox
proportional hazard models. The dependent variables
in the multivariable Cox proportional hazard models
were OS and PFS. The independent variables were:
age, gender, IPI score (0–5 on a continuous scale) and
BMI. The Z-scores of skeletal muscle index and muscle
density and the presence of LMM, LMD, and both
LMM and LMD were added to the multivariable Cox
proportional hazard models in separate analyses (i.e.
one variable was added at a time).
Variance inflation factors were calculated to assess
the degree of multicollinearity among the independ-
ent variables in the Cox proportional hazard models.
The proportional hazards assumption was assessed by
testing the interaction effects between independent
variables and follow-up time in a Cox proportion haz-
ards model with time-dependent covariates. All analy-
ses were performed using SPSS version 24.0 (SPSS Inc.,
Chicago, IL, USA) with a two-sided significance level
of 0.05.
Results
Patient characteristics
Between 2006 and 2015, 252 patients with DLBCL
were identified. Of these patients, 55 patients did not
receive R-CHOP, 13 patients were referred to another
hospital, 7 passed away before treatment, 4 patients
were excluded because no CT-scan prior to treatment
was available, 3 had a second malignancy, 2 had a his-
tory of prior lymphoma, for 1 patient no data were
available about weight and length before start of
chemotherapy and 3 patients were excluded because
CT-based muscle measurement was not possible due
to technical problems. In total, 164 patients were
included in the analysis. The median age was
64.5 years (IQR: 54.3–74.0 years). Two-thirds of the
patients were above 60 years of age. The median IPI
score was 2 (IQR: 1–3) and complete response after
therapy was reached in 129 patients (79%). The
median duration of follow-up was 57months (IQR:
27.3–85.8months). No patients were lost to follow-up
(Table 1).
Prevalence of LMM and LMD and comparison
with a healthy reference population
Median muscle mass in the entire group with DLBCL
was 40.5 cm2/m2 (IQR: 35.3–46.6 cm2/m2). Median
muscle mass in the healthy population was
47.4 cm2/m2 [18]. The median Z-score was 1.04 (IQR:
1.69 to 0.58) in males and 0.78 (IQR: 1.62 to
0.29) in females with DLBCL. The median muscle
mass in both males and females with DLBCL was sig-
nificantly lower compared to their healthy counter-
parts (p< 0.001). In the healthy population, a Z-score
of 1 corresponded with the worst 16% of the
healthy population, whereas 49% of the patients with
DLBCL had a Z-score of 1 and were accordingly
considered having LMM. The incidence of dose-limit-
ing or dose-interrupting toxicity, premature termin-
ation of treatment and chemotherapy dose did not
significantly differ between patients with LMM and
without LMM. Other patient characteristics were also
not significantly different between patients with and
without LMM (Table 1).
Similar to the findings on muscle mass, median
muscle density was significantly lower in the patients
with DLBCL compared to the healthy reference popu-
lation (37.5 HU (IQR: 28.7–44.4 HU) vs. 44 HU [18],
p< 0.001). 23% of the patients were considered hav-
ing LMD and these patients were older (median age
70.0 vs. 63.0 years, p¼ 0.05) than patients without
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LMD. Patients with LMD also more often experienced
premature termination of chemotherapy (28.9% vs.
12.1%, p¼ 0.02), while the dosages of received cycles
remained similar. The main reasons for premature
treatment termination were treatment toxicity (27.3%
in patients with LMD vs. 20.0% in patients without
LMD) and death (36.4% in patients with LMD vs.
13.3% in patients without LMD) (Table 1).
Multivariable logistic regression models revealed that
the presence of either LMM or LMD was not signifi-
cantly associated with age, gender, IPI score or the
presence of comorbidity.
Table 1. Patient characteristics.
LMM
N¼ 80 (49%)
No LMM
N¼ 84 (51%) p value
LMD
N¼ 38 (23%)
No LMD
N¼ 126 (77%) p value
Age (median) (IQR) 64.0 (54.2–74.8) 65.0 (54.8–73.8) 0.90 70.0 (61.0–76.0) 63.0 (54.0–73.0) 0.05
>60 years 52 (65.0) 55 (65.5) 1.00 31 (81.6) 76 (60.3) 0.02
Male 42 (52.5) 38 (45.2) 0.44 18 (47.4) 62 (49.2) 0.86
BMI 24.6 (22.7–26.3) 25.0 (22.5–28.7) 0.26 24.2 (22.5–26.7) 24.9 (22.7–28.4) 0.36
IPI score 0.42 0.57
Low riska 49 (61.3) 57 (67.9) 23 (60.5) 83 (65.9)
High riskb 31 (38.8) 27 (32.1) 15 (39.5) 43 (34.1)
Comorbidity presentc 15 (18.8) 12 (14.3) 0.53 7 (18.4) 20 (15.9) 0.80
Response to chemo-immunotherapy 0.10 0.08
Complete 63 (78.8) 66 (78.6) 26 (68.4) 103 (81.7)
Partial 3 (3.8) 8 (9.5) 3 (7.9) 8 (6.3)
Refractory 0 3 (3.6) 2 (5.3) 1 (0.8)
Progressive 5 (6.3) 3 (3.6) 1 (2.6) 7 (5.6)
Not assessable 9 (11.3) 4 (4.8) 6 (15.8) 7 (5.6)
Toxicityd 33 (41.3) 26 (31.0) 0.20 30 (52.6) 39 (31.0) 0.02
Hypoalbuminemia 19 (23.8) 13 (15.5) 0.24 10 (26.3) 22 (17.5) 0.25
Chemo-immunotherapy cycles received 6.0 (4.0–8.0) 6.0 (4.8–8.0) 0.93 6.0 (3.8–7.3) 6.0 (5.0–8.0) 0.27
Cumulative dosage (mg)
Vincristine 12.0 (6.0–13.0) 10.5 (6.0–12.0) 0.47 12.0 (6.0–12.0) 11.0 (6.0–14.0) 0.58
Doxorubicin 600 (300–750) 557.5 (345–717.5) 0.50 550 (285–700) 592.5 (330–720) 0.32
Cyclophosphamide 9000 (4200–11,200) 8700 (6400–10,950) 0.55 8350 (3975–10,550) 8950 (4900–11,200) 0.24
BSA (m2) 1.90 (1.70–2.08) 1.80 (1.70–1.95) 0.10 1.84 (1.69–2.05) 1.88 (1.70–2.01) 0.87
SMI (cm2/m2) 35.0 (31.7–41.8) 44.3 (39.8–50.5) <0.001 39.6 (33.2–42.2) 41.7 (35.9–47.9) 0.03
MD (HU) 34.7 (28.7–43.8) 38.4 (28.7–45.2) 0.25 25.1 (21.2–31.0) 39.4 (33.1–46.1) <0.001
Both LMM and LMD
N¼ 22 (13%)
Others
N¼ 142 (87%) p value
Age (median) (IQR) 68.5 (60.8–76.8) 64.0 (54.0–73.3) 0.25
>60 years 18 (81.8) 89 (62.7) 0.10
Male 12 (54.5) 68 (47.9) 0.65
BMI 24.4 (22.5–26.4) 24.7 (22.6–27.9) 0.51
IPI score 0.63
Low riska 13 (59.1) 93 (65.5)
High riskb 9 (40.9) 49 (34.5)
Comorbidity presentc 5 (22.7) 22 (15.5) 0.37
Response to chemo-immunotherapy 0.01
Complete 13 (59.1) 116 (81.7)
Partial 2 (9.1) 9 (6.3)
Refractory 0 3 (2.1)
Progressive 1 (4.5) 7 (4.9)
Not assessable 6 (27.3) 7 (4.9)
Toxicityd 12 (54.5) 47 (33.1) 0.06
Hypoalbuminemia 7 (31.8) 25 (17.6) 0.15
Chemo-immunotherapy cycles received 6.0 (3.0–6.0) 6.0 (5.0–8.0) 0.04
Cumulative dosage (mg)
Vincristine 12.0 (5.0–12.0) 11.0 (6.0–13.1) 0.47
Doxorubicin 520 (270–705) 600 (375–720) 0.25
Cyclophosphamide 7060 (3500–93,750) 9000 (5100–11,200) 0.06
BSA (m2) 1.96 (1.68–2.09) 1.85 (1.70–2.00) 0.53
SMI (cm2/m2) 34.4 (30.7–40.8) 41.5 (36.5–47.9) <0.001
MD (HU) 26.3 (17.7–31.0) 38.6 (31.0–45.6) <0.001
Continuous variables are described as median (interquartile range). Categorical variables are described as numbers (%).
BMI: body mass index; BSA: body surface area; IPI: international prognostic index; IQR: interquartile range; LMD: low muscle density; LMM: low muscle
mass; LSMI: lumbar skeletal muscle index; MD: muscle density.
aLow-risk DLBCL: IPI 0–2.
bHigh-risk DLBCL: IPI 3–5.
cComorbidity was considered to be present in case of the presence of either rheumatoid diseases, diabetes mellitus, chronic liver disease or cardiovascu-
lar disease (cardiac events in the past, cardiac failure or known coronary arteriosclerosis).
dThe presence of dose-limiting or dose-interrupting toxicity or definitive termination of R-CHOP due to toxicity.
p-values are highlighted in bold.
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A minority of the patients (n¼ 22, 13%) had both
LMM and LMD. These patients more frequently did
not complete the planned treatment (31.8% vs. 13.6%)
and as expected, were therefore less likely to achieve
a complete response (59.1% vs. 81.7%, p¼ 0.01). After
adjustment for age, gender, IPI score, BMI, and comor-
bidity, the combination of LMM and LMD was still
associated with premature termination of chemo-
immunotherapy (multivariable OR 2.84, 95% CI:
1.00–1.81, p¼ 0.05). No significant differences in the
prevalence of high-risk lymphoma (IPI score >2) or
comorbidity were established between patients with
and without LMM or LMD (Table 1).
Survival
The median OS in the entire cohort was not reached
during follow-up. The 5-year OS was 75.6%. At the
end of follow-up, a total of 50 patients (30.5%) had
died. Both LMM and muscle mass on a continuous
scale were not significantly associated with OS (multi-
variable HR: 0.95, 95% CI: 0.74–1.23, p¼ 0.71 and HR:
1.16, 95% CI: 0.66–2.03, p¼ 0.61, respectively) (Table
2). Patients with LMD had a shorter OS than patients
without LMD (median OS 118months, 95% CI:
47.4–198.6months vs. median OS not reached,
p¼ 0.02) (Figure 1(C)), but no significant difference in
survival was observed after adjustment for age, gen-
der, BMI and IPI score (Table 2). Only the combination
of both LMM and LMD was significantly associated
with shorter survival, also after adjustment for other
clinical factors, including IPI score (multivariable HR:
2.42, 95% CI: 1.27–4.63, p¼ 0.01) (Table 2).
Similar results were observed for PFS. The 5-year
PFS was 75.0% and only the combination of both
LMM and LMD was independently associated with
shorter PFS (multivariable HR: 2.16, 95% CI: 1.14–4.08,
p¼ 0.02) (Table 3). No significant violations of the pro-
portional hazards assumption were detected.
Discussion
This study showed that the combination of LMM and
LMD was an independent risk factor for shorter OS
and PFS. Furthermore, these patients frequently dis-
continued R-CHOP and were subsequently less likely
to achieve a CR. In a study involving 187 DLBCL
patients, CR-rate did not differ between patients with
LMM and patients with normal muscle mass if it was
possible to administer all planned treatment cycles
[10]. Therefore it is possible that premature termin-
ation of treatment is the cause of the diminished CR-
rate, highlighting the possibility that targeting LMM/
LMD might result in a higher CR-rate, thereby improv-
ing survival. This is supported by the fact that OS and
PFS in our study were highly comparable, indicating
that the cause of death is mainly because of progres-
sive disease.
In a study involving elderly DLBCL patients
>70 years of age, LMM was an independent prognos-
tic factor for OS (HR: 3.22, 95% CI: 1.73–5.98,
p¼ 0.0002) and PFS (HR: 2.24, 95% CI: 1.12–4.12,
p¼ 0.01) [8]. This effect was not clearly observed in
younger patients, which is also in contrast with the
prognostic impact of LMM in several solid malignan-
cies. This implicates that firstly, prognostic impact of
muscle parameters differs between specific tumor-
and treatment settings and therefore, the most suit-
able body composition parameter for clinical applic-
ability differs accordingly. Secondly, the measurement
of muscle mass might be especially clinically relevant
in the older patient, where the presence of LMM
might indicate undetected decreased physical reserve.
This is supported by the fact that LMM was not associ-
ated with impaired physical performance and high IPI
score on multiple occasions [8,19]. Also, it has been
reported that the non-cancer-related mortality because
of treatment toxicity and adverse events is higher in
patients with LMM compared to patients with normal
muscle mass [20], indicating that these patients are
frail. In younger patients with DLBCL, the prognostic
impact of LMM should be interpreted with caution.
Overall, accumulating evidence shows that LMM
and LMD in cancer patients result in more treatment
toxicity [4,21], more postoperative complications [22],
Table 2. Cox proportional hazard models OS.
Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Age 1.03 1.01–1.06 0.01 1.02 1.00–1.05 0.07
Male 0.88 0.51–1.55 0.67 1.14 0.63–2.05 0.66
BMI 0.92 0.86–0.98 0.01 0.94 0.88–1.01 0.10
IPI 1.34 1.34–2.20 <0.001 1.51 1.16–1.97 0.003
Z-score SMI
(continuous)
0.90 0.71–1.13 0.35 0.95 0.74–1.23 0.71
Z-score MD
(continuous)
0.73 0.56–1.94 0.02 0.88 0.66–1.17 0.38
LMMa 1.24 0.71–2.17 0.45 1.16 0.66–2.03 0.61
LMDb 2.05 1.14–3.65 0.02 1.68 0.94–3.03 0.08
Both LMM and LMD 2.74 1.45–5.18 0.002 2.42 1.27–4.63 0.01
A multivariable Cox proportional hazard model was performed with all
basic patient characteristics (above the line), after which each muscle par-
ameter (below the line) was added in a separate Cox proportional haz-
ard model.
BMI: body mass index; IPI: international prognostic index; LMD: low
muscle density; LMM: low muscle mass; MD: muscle density; OS: overall
survival; SMI: skeletal muscle index.
aLMM: Z-score <1.
bLMD: Z-score <1.
p-values are highlighted in bold.
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shorter survival [5,17], and decreased quality of life
[23]. One explanation may be that pharmacokinetic
variations of cytotoxic drugs occur depending on
body composition [24]. Muscle measurement may
help to guide optimization of chemotherapy dosage
in order to reduce toxicity, while still maintaining
oncological efficacy. Therefore, it is important to iden-
tify which muscle parameters (muscle mass, muscle
density, fat tissue, muscle strength, physical
performance measures or combinations of all) have
the best clinical prognostic value. In our study, LMD
was a better prognostic marker for OS than LMM and
the combination of LMM and LMD had more prognos-
tic impact than solitary LMM or LMD. This is in line
with studies in patients with DLBCL [11] and several
other malignancies [12–14]. A study in metastatic
breast cancer patients also revealed the superior prog-
nostic relevance of LMMþ LMD compared to solitary
Figure 1. Kaplan–Meier curves for OS (A, C, E) and PFS (B, D, F) for patients with LMM vs. no LMM, with LMD vs. no LMD and
LMMþ LMD vs. all others.
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LMM or LMD [21]. The assumption that LMD has more
prognostic impact than LMM is persuasive, considering
the fact that LMD is especially observed with
advanced age [25] and in the presence of comorbid-
ities, mainly cardiovascular disease [26]. In these set-
tings, LMD is a sign of a deregulated fat metabolism
in muscle fibers, resulting in fatty infiltration of muscle
and a higher production of pro-inflammatory cyto-
kines. In addition to the prognostic significance of
LMM and LMD at the start of the treatment, it is
important to note that DLBCL patients also develop
long-term body composition changes as a result of
chemotherapeutic treatment. In a longitudinal retro-
spective study of 342 DLBCL survivors, the prevalence
of LMM after chemotherapy was 37.9%, whereas
20.7% of these patients did not have LMM at the start
of treatment [27]. In another study with DLBCL
patients undergoing allogeneic hematopoietic stem
cell transplantation (HSCT), the prevalence of LMM
was 55% at baseline and 75% 2.5 years after allogeneic
HSCT [28]. In these studies, the development of LMM
after chemotherapy was associated with higher age,
>5% weight loss during chemotherapy and having
LMM at baseline, therefore possibly indicating vulner-
able patients. The prognostic impact of muscle loss
during chemotherapy is yet to be established.
Our study has several limitations. This was a retro-
spective study, where selection bias might have
occurred. Furthermore, because of the sample size,
there may not have been enough power to truly estab-
lish the lack of prognostic impact of solitary LMD. This
needs to be confirmed in a larger patient cohort. Also,
the number of younger patients (<70 years) was rela-
tively small. More studies are needed to explore the
prognostic impact of muscle measures in younger
patients with DLBCL. However, this study compared
muscle measures in a cancer population with healthy
reference subjects in a first attempt to standardize
muscle measurements worldwide. The estimated for-
mula to calculate a gender-, age- and BMI-specific Z-
score has the potential to easily identify patients with
LMM or LMD. It must be noted that the healthy popu-
lation in this study is from the Netherlands and mainly
Caucasian. Therefore, this formula might not be applic-
able in all geographic regions. Other healthy reference
populations need to be established according to ethni-
city and geographic region.
In conclusion, the combination of LMM and LMD is
independently associated with impaired PFS and OS in
DLBCL patients. The presence of LMM and LMD was
not related to preexisting comorbidities or unfavorable
lymphoma characteristics, indicating that the combin-
ation of LMM and LMD is a lymphoma-independent
risk factor for shorter survival, possibly because it
more often results in premature termination of
chemotherapy and as a consequence, a lower CR-rate.
Studies are needed to investigate the prognostic
impact of LMM and LMD in DLBCL prospectively and
to investigate if optimization of LMM and LMD during
chemo-immunotherapy results in a higher CR-rate and
prolonged survival. This might result in the identifica-
tion of possible roles for muscle measurements in
drug dosing and treatment decision-making. To
achieve that, standardization of muscle measurement
is needed. We recommend to measure both LMM and
LMD or to measure sarcopenia, which is the combin-
ation of LMM and impaired muscle strength or phys-
ical performance. To define patients with LMM or
LMD, the Z-scores in this study derived from the
healthy reference population could be used after val-
idation in an independent dataset.
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Table 3. Cox proportional hazard models PFS.
Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Age 1.03 1.01–1.05 0.01 1.02 1.00–1.04 0.11
Male 0.90 0.53–1.54 0.70 1.11 0.63–1.94 0.72
BMI 0.94 0.89–0.94 0.94 0.97 0.91–1.03 0.31
IPI 1.66 1.31–2.10 <0.001 1.51 1.16–1.95 0.002
Z-score SMI
(continuous)
0.92 0.74–1.14 0.44 0.97 0.77–1.23 0.80
Z-score MA
(continuous)
0.77 0.60–1.99 0.04 0.93 0.70–1.22 0.59
LMM 1.26 0.74–2.16 0.39 1.19 0.69–2.04 0.53
LMD 1.74 0.99–3.08 0.06 1.43 0.80–2.55 0.23
Both LMM and LMD 2.48 1.32–4.64 0.01 2.16 1.14–4.08 0.02
A multivariable Cox proportional hazard model was performed with all
basic patient characteristics (above the line), after which each muscle par-
ameter (below the line) was added to this model in a separate Cox pro-
portional hazard model.
BMI: body mass index; IPI: international prognostic index; LMD: low
muscle density; LMM: low muscle mass; MD: muscle density; PFS: pro-
gression free survival; SMI: skeletal muscle index.
p-values are highlighted in bold.
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